Sun Pharma Wins Reprieve as CESTAT Sends Back Rs. 3.90 Crore Excise Demand for Re-Assessment Over EOU DTA Sales and Deemed Exports – Juris Hour
The Customs, Excise, and Service Tax Appellate Tribunal (CESTAT) has remanded a Rs. 3.90 crore excise demand against Sun Pharmaceutical Industries Ltd. regarding sales from an Export Oriented Unit (EOU) to a Domestic Tariff Area (DTA). The tribunal has directed the authorities to recalculate the deemed exports and the corresponding excise duty liability.
The dispute arose from the company’s sales from its EOU to its DTA unit, which were treated as deemed exports under the Export and Import Policy. The excise authorities demanded duty on these sales, claiming that they were not genuine exports. Sun Pharma argued that the sales were eligible for exemption under the exemption notification, as they were deemed exports.
The CESTAT observed that the excise authorities had not properly verified the deemed export benefits claimed by the company. The tribunal noted that the authorities had not considered the export proceeds realized by the company and had not verified the consumption of the goods in the DTA.
The CESTAT held that the excise authorities’ demand was not sustainable and remanded the matter to the original authority to recalculate the deemed exports and the corresponding excise duty liability. The tribunal directed the authorities to consider the export proceeds realized by the company and to verify the consumption of the goods in the DTA.
The CESTAT’s order is significant, as it clarifies the treatment of sales from an EOU to a DTA under the excise law. The order also highlights the importance of proper verification and calculation of deemed export benefits. The remand order will allow the authorities to re-examine the company’s claims and calculate the correct excise duty liability.
The case emphasizes the need for exporters to maintain accurate records and documentation to support their claims for deemed export benefits. It also underscores the importance of proper verification and calculation by the excise authorities to ensure that the correct excise duty liability is determined. The CESTAT’s order will provide guidance to other exporters and excise authorities in similar cases, ensuring consistency and clarity in the application of the excise law.
Experts from Apollo, Aster CMI, and Fortis warn that snoring may be a warning sign of underlying heart issues, citing five key reasons.
Persistent, loud snoring is often dismissed as a harmless nighttime habit, but it can be a warning sign of obstructive sleep apnea (OSA), a condition that puts the heart under constant stress. According to leading medical experts, OSA can lead to high blood pressure, irregular heart rhythms, and eventually, heart failure. Dr. Varun Bansal, a senior consultant at Indraprastha Apollo Hospitals, states that snoring is frequently trivialized, yet its impact on the body is profound, and is strongly linked with changes in the way the heart and blood vessels work.
Experts have identified five critical ways that chronic snoring and sleep apnea damage the cardiovascular system:
- Oxygen deprivation and heart stress: When snoring transitions into sleep apnea, the airway becomes blocked, causing breathing to stop for seconds or even a minute, leading to a state of emergency and triggering stress systems that spike the heart rate.
- The link to ‘stubborn’ high blood pressure: Blood pressure stays elevated or surges during apnea episodes, making the heart muscle stiff and less functional over time.
- Dangerous heart rhythm disturbances: The repeated ‘stop-start’ nature of breathing during sleep stimulates stress hormones like adrenaline, increasing the risk of Atrial Fibrillation (AFib) and other irregular heartbeats.
- Inflammation and vascular damage: Repeated breathing pauses trigger systemic inflammation, damaging the lining of the blood vessels and speeding up plaque buildup (atherosclerosis), which can lead to heart attacks and weakened heart function.
- The ‘vicious cycle’ of metabolic stress: Snoring is tightly correlated with abdominal obesity and diabetes, and sleep disruption interferes with hunger hormones, leading to weight gain, which in turn worsens snoring.
The warning signs of sleep apnea that shouldn’t be ignored include daytime fatigue, gasping for air or choking sounds during sleep, morning headaches, and high blood pressure that doesn’t respond well to medication. While occasional snoring due to a cold or alcohol use is generally not dangerous, doctors urge a medical evaluation if snoring is accompanied by these symptoms.
The good news is that heart damage caused by sleep apnea is often preventable and sometimes reversible if caught early. Treatments like CPAP devices, weight management, and lifestyle changes can stabilize heart rhythms and lower blood pressure. If you or a loved one are chronic snorers, a sleep study could be the first step in protecting your heart’s future. It’s essential to seek medical advice if you’re concerned about snoring or sleep apnea, as early detection and treatment can make a significant difference in preventing long-term heart damage.
Glenmark Pharmaceuticals USA has introduced a multiple-dose vial of epinephrine injection.
Glenmark Pharmaceuticals Inc, USA, has launched Epinephrine Injection USP, a bioequivalent and therapeutically equivalent product to the reference listed drug manufactured by BPI Labs, LLC. The product is available in a 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial and is intended for the U.S. market. According to IQVIA sales data, the Epinephrine Injection market had annual sales of approximately USD 67.6 million for the 12 months ending October 2025. This launch expands Glenmark’s institutional product portfolio and reinforces its commitment to providing high-quality, affordable treatment options.
Glenmark Pharmaceuticals Limited is a prominent Indian multinational pharmaceutical company that has been in operation since 1977. The company has grown from its origins in generic medicines and active pharmaceutical ingredients (APIs) to become a research-led global healthcare organization with a presence in over 80 countries. Glenmark’s core therapeutic expertise includes respiratory, dermatology, oncology, cardiovascular, and anti-infective treatments, with multiple R&D centres and manufacturing facilities across India and internationally.
In recent years, Glenmark has diversified into innovative drug development and biosimilars, while maintaining a strong portfolio of branded generics in high-growth markets. The company has also entered strategic collaborations and licensing deals to advance novel therapies, particularly in oncology. Despite facing quality control challenges in some manufacturing facilities, Glenmark continues to pursue a transformation towards a more innovation-centric business model aimed at increasing its branded portfolio and long-term global competitiveness.
The launch of Epinephrine Injection USP is part of Glenmark’s strategy to strengthen its institutional channel presence and improve access to essential medicines. According to Marc Kikuchi, President and Business Head for North America at Glenmark, the launch supports the company’s commitment to providing high-quality, affordable treatment options. With its robust revenue growth and expanding demand in key markets such as North America and Europe, Glenmark is well-positioned to continue its growth and expansion in the global pharmaceutical market.
The US FDA has issued a recall for an antifungal shampoo manufactured by Sun Pharma.
The US Food and Drug Administration (USFDA) has announced a recall of over 17,000 units of antifungal shampoo, Ciclopirox Shampoo, due to manufacturing issues. The recall was initiated by Taro Pharmaceutical Industries, the US arm of Sun Pharma, on December 9. The shampoo is used to treat seborrheic dermatitis, a condition that causes dry, flaky, and itchy skin. The recall was classified as a Class II recall, which means that the product’s use may lead to temporary or medically reversible health consequences, but the likelihood of serious adverse health outcomes is minimal.
The recall was due to “failed impurity/degradation specifications,” according to the USFDA. Taro Pharmaceutical Industries is a private company and a wholly-owned subsidiary of Sun Pharma, which acquired the Israel-based company in a deal valued at $347.73 million last year. Sun Pharma has been the majority shareholder of Taro since 2010. Taro primarily focuses on dermatology and produces a wide range of prescription and over-the-counter products.
The recall is a setback for Sun Pharma, which is a leading exporter to the US market. In the second quarter of FY26, the company reported revenue of Rs 14,478 crore, with a net profit of Rs 3,118 crore, a 2.56% increase year-on-year. However, formulation sales in the US declined 4.1% to $496 million. The recall highlights the importance of quality control and regulatory compliance in the pharmaceutical industry.
The USFDA’s Enforcement Report noted that the recall was nationwide and affected 17,664 units of the Ciclopirox Shampoo. The company has taken prompt action to address the issue, and the recall is expected to minimize any potential harm to consumers. The incident serves as a reminder of the need for pharmaceutical companies to maintain high standards of quality and manufacturing practices to ensure the safety and efficacy of their products.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.